The dosage of Zoryve for children 6 to 11 is the same as for those over the age of 12. The list price is same for both pediatrics and adults — $825 per tube.
FDA has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children 6 to 11 years of age. Developed by Arcutis Biotherapeutics, Zoryve is a once-daily, steroid-free cream. This approval expands Zoryve indications; it was approved in July 2022 to treat those 12 years and older for the same indication.
The dosage for children 6 to 11 is the same as for those over the age of 12 and pricing is same for both pediatrics and adults, according to an Arcutis spokesperson.
Zoryve’s wholesale acquisition cost is $825 per tube. Those with commercial drug insurance may be eligible for the Zoryve Direct Savings Card. Patients may pay as little as $25 if their commercial drug insurance covers Zoryve, and $75 if their commercial drug insurance currently does not. Individual patient savings are limited to $875 per fill and $5,000 in maximum total savings per calendar year.
As with adults and adolescents, plaque psoriasis is the most common form of psoriasis in children 6 to 11 years of age, and presents with very similar clinical features, including “plaques,” or raised, red areas of skin covered with a silver or white layer of dead skin cells.
“In children, psoriasis ranges from mild to severe, and more often appears on sensitive areas including the face and skin folds, compared with adults. Topical steroids are commonly recommended medications for the treatment of pediatric psoriasis. However, they come with safety and tolerability concerns related to long-term use. Steroid-free topical treatments that can be used on sensitive areas are especially needed for managing plaque psoriasis in younger children,” Adelaide A. Hebert, M.D., professor and chief of pediatric dermatology at McGovern Medical School at UTHealth Houston and Children’s Memorial Hermann, said in a press release.
The additional approval is based on data from a four-week study Maximal Usage Systemic Exposure (MUSE) in children 6 to 11 years of age with plaque psoriasis. Pharmacokinetic, safety, tolerability, and efficacy data from this study were generally consistent with data from the DERMIS-1 and DERMIS-2 pivotal phase 3 trials in adults. The use Zoryve is children 2 to 5 years of age is being evaluated in second MUSE study, and an open label extension study is ongoing to assess the long-term safety of roflumilast cream.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More